Solara Active Pharma Sciences Limited held its Ninth Annual General Meeting (AGM) on Friday, September 18, 2026, from 10:30 A.M. to 11:40 A.M. IST through video conferencing in compliance with the Companies Act, 2013, SEBI Listing Regulations, 2015, and relevant circulars from MCA and SEBI.

Meeting Participants

The following directors and management officials attended the meeting:

  • Mr. R. Ramakrishnan - Independent Director & Chairman of the Board, Audit Committee
  • Dr. Kausalya Santhanam - Independent Director & Chairperson of Stakeholders Relationship Committee & CSR Committee
  • Dr. Rajendra Kumar Srivastava - Independent Director & Chairman of Nomination and Remuneration Committee
  • Mr. Rajiv Vijay Nabar - Independent Director, Chairman of Risk Management Committee
  • Mr. Manish Gupta - Non-Executive Director
  • Mr. Sandeep Shashikantha Rao - Managing Director & Chief Executive Officer (CEO)
  • Mr. Mohanraj Sanjeevi - Whole Time Director & Chief Human Resources Officer (CHRO)
  • Mr. Sarat Kumar Asuri - Chief Financial Officer (CFO)
  • Ms. Pooja Jaya Kumar - Company Secretary & Compliance Officer
  • Mr. Raghavan Venkatramani - Assistant Vice President - Accounts

Other Invitees Present

Representatives from Deloitte Haskins & Sells LLP (Statutory Auditors), Grant Thornton Bharat LLP (Internal Auditors), Mrs. Parimala Natrajan (Secretarial Auditor), Mr. Preetham Hebbar (Practising Company Secretary, Scrutinizer for e-voting), and Mr. Nagaraj V from Cameo Corporate Services Limited (Registrar and Share Transfer Agent) were also present.

Meeting Proceedings

Ms. Pooja Jaya Kumar confirmed quorum requirements were met and requested Mr. R. Ramakrishnan to chair the meeting. Mr. Sandeep Shashikantha Rao (Managing Director & CEO) and Mr. Sarat Kumar Asuri (CFO) presented the financial and business performance for Financial Year 2025-26. Shareholder queries were addressed by management.

The AGM Notice, Board's Report, and Auditor's Report for FY ended March 31, 2026, were taken as read since they had been previously circulated. The Auditor's Reports on Standalone and Consolidated Financial Statements contained no qualifications, observations, or adverse remarks.

Business Transacted

The following agenda items from the Notice dated August 21, 2026, were approved:

1. Ordinary Business: Adoption of Audited Standalone Financial Statements for FY ended March 31, 2026 (Ordinary Resolution)

2. Adoption of Audited Consolidated Financial Statements for FY ended March 31, 2026 (Ordinary Resolution)

3. Appointment of Mr. Arun Kumar Pillai (DIN: 00084845), who retires by rotation, as Non-Executive Director (Ordinary Resolution)

4. Special Business: Ratification of remuneration payable to Cost Auditor for financial year 2026-27 (Ordinary Resolution)

5. Approval for Material Related Party Transactions/Contracts/Arrangements with Strides Pharma Science Limited up to ₹480 crores (Ordinary Resolution)

Voting and Results

Shareholders who hadn't voted through remote e-voting were given an additional 30 minutes to vote electronically during the meeting. Voting results along with the Scrutinizer's Report were scheduled to be declared by Tuesday, September 22, 2026 (within two working days), and would be posted on the Company's website, RTA's website, and filed with both stock exchanges.